Asleep Recruits Handok as Second Pharma Partner to Distribute ChronoTrack Sleep Device

Asleep, a Seoul-based sleep artificial intelligence company, is widening the sales channel for its digital medical device ChronoTrack by adding pharmaceutical firm Handok as a domestic distributor. The two companies signed a distribution and sales agreement for the sleep-rhythm recording device on August 19, Asleep said the following day. The deal makes Handok the second established Korean pharmaceutical company to carry the product, following an earlier arrangement with Chong Kun Dang — a pattern that shows a digital health startup renting the reach of legacy drugmakers rather than building its own sales force.

A Sleep Recorder That Skips the Wearable

ChronoTrack is registered as a digital medical device that records a user’s sleep rhythm, and its distinguishing claim is that it performs sleep analysis without requiring a wearable sensor. That places it apart from the wristbands and rings that dominate consumer sleep tracking: instead of asking users to strap on hardware, Asleep’s approach builds on its core business of AI-driven sleep analysis. For a pharmaceutical distributor, a device with no wearable component is also a simpler product to move — there is less hardware logistics, and the value sits in the software and the data it produces.

Why Asleep Keeps Signing Drugmakers

The choice of partners is the more telling part of the announcement. Handok, a listed mid-sized pharmaceutical company, and Chong Kun Dang, one of Korea’s larger drugmakers, both bring something a sleep-tech startup cannot quickly replicate: standing relationships with hospitals, clinics and pharmacies, and sales organizations accustomed to selling regulated medical products. Digital medical devices in Korea must travel through the same institutional channels as conventional therapeutics if they are to be prescribed or recommended by clinicians, and channel access — not technology — is typically the bottleneck for young companies in the category.

For the pharmaceutical companies, the logic runs in the other direction. Korean drugmakers have been adding digital health products to their portfolios as a low-capital way to participate in a growing segment, and distribution agreements let them test demand for devices like ChronoTrack without funding the underlying development.

What a Two-Distributor Network Changes

With two pharmaceutical partners now carrying the same device, Asleep moves from a single-channel experiment to something closer to a genuine domestic distribution network. Overlapping distributors can create channel conflict, but in pharmaceutical sales the more common outcome is territorial or institutional segmentation, with each partner covering the accounts where its own relationships are strongest. Whether the arrangement translates into meaningful sales volume remains to be demonstrated — neither company disclosed financial terms or sales targets — but the sequencing suggests the first partnership performed well enough to justify a second.

The broader test for Asleep, and for Korea’s sleep-tech sector, is whether devices that record and analyze sleep can graduate from wellness curiosities into products that clinicians order routinely. Recruiting the companies that already sit in the clinician’s supply chain is the most direct route to finding out.